Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:10 AM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 10,533 matching trials from the local directory fallback.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 2 Interventional Results available

A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day

NCT03878446
View directory record Official record
Conditions
Short Stature Children Born Small for Gestational Age (SGA)
Interventions
Norditropin®, Somapacitan
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 11 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • Boise, Idaho + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 8:58 PM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

NCT03776487
View directory record Official record
Conditions
Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Localized Gastric Carcinoma, Localized Gastroesophageal Junction Adenocarcinoma, Pathologic Stage 0 Gastric Cancer AJCC v8, Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage I Gastric Cancer AJCC v8, Pathologic Stage IA Gastric Cancer AJCC v8, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Fluorouracil, Intensity-Modulated Radiation Therapy, Ipilimumab, Nivolumab, Oxaliplatin, Therapeutic Conventional Surgery
Drug · Radiation · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 8:19 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Sleep Deprivation and Recovery Sleep on Emotional Memory and Affective Reactivity

NCT03767426
View directory record Official record
Conditions
Sleep, Sleep Deprivation
Interventions
Daytime nap, Sleep Deprivation
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 6:37 PM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT03763162
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab, Dexamethasone, Ixazomib, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 1:18 AM EDT
Active, not recruiting Not applicable Interventional

Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment

NCT03731585
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Behavioral Intervention, Educational Intervention, Questionnaire Administration, Support Group Therapy
Behavioral · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 8:03 PM EDT
Active, not recruiting Early Phase 1 Interventional

Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma

NCT03680586
View directory record Official record
Conditions
Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Interventions
Radiation Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 1:47 AM EDT
Active, not recruiting No phase listed Observational

A Quality of Life Study in Patients Undergoing Percutaneous Biliary Drainage

NCT03672019
View directory record Official record
Conditions
Malignant Biliary Obstruction
Interventions
FACT-Hep
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 1:10 AM EDT
Active, not recruiting Not applicable Interventional

Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center

NCT03671226
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Caregiver, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm
Interventions
Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 5:51 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer

NCT03637816
View directory record Official record
Conditions
Anorexia, Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Anamorelin Hydrochloride, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 12:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

NCT03581292
View directory record Official record
Conditions
Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions
Radiation Therapy, Temozolomide, Veliparib
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 25 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
145
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 10:19 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

NCT03546972
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Ductal Breast Carcinoma In Situ, Obesity, Overweight, Premalignant Lesion
Interventions
Behavioral, Psychological or Informational Intervention, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 5:10 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

NCT03525873
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Laboratory Biomarker Analysis, Methylphenidate, Physical Activity, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 5:32 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Use of a Smartphone Mobile Application (App) to Enhance Smoking Cessation Treatment

NCT03519451
View directory record Official record
Conditions
Current Every Day Smoker, Depression, Tobacco Use Disorder
Interventions
Internet-Based Intervention, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 4:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

NCT03504644
View directory record Official record
Conditions
Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Recurrent T Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Lumbar Puncture, Positron Emission Tomography, Venetoclax, Vincristine Liposomal, Vincristine Sulfate
Procedure · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
163
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 11, 2026, 8:06 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

NCT03419234
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel, Prednisone
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
665
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 11:21 AM EDT
Active, not recruiting Phase 1 Interventional

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

NCT03132454
View directory record Official record
Conditions
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine, Dexamethasone, Palbociclib, Sorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 4:31 PM EDT
Active, not recruiting Not applicable Interventional

Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers

NCT03114501
View directory record Official record
Conditions
Head and Neck Cancer, Malignant Neoplasms of Lip Oral Cavity and Pharynx
Interventions
Symptom Questionnaires, Yoga, Yoga Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 10:00 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

NCT02979873
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Sirolimus
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 12:07 AM EDT
Active, not recruiting Phase 2 Interventional

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

NCT02960555
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Isatuximab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 4:52 PM EDT
Active, not recruiting Phase 2 Interventional

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

NCT02876107
View directory record Official record
Conditions
Breast Carcinoma, Breast Lump, Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Peau d'Orange, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Panitumumab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 1:54 PM EDT
Active, not recruiting Not applicable Interventional

The Beans to Enrich the Gut Microbiome vs. Obesity's Negative Effects (BE GONE) Trial

NCT02843425
View directory record Official record
Conditions
Colorectal Cancer Prevention
Interventions
Navy Beans (Canned), Regular Diet
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 2:58 PM EDT
Active, not recruiting No phase listed Observational

Use of ctDNA for Monitoring of Stage III Colorectal Cancer

NCT02842203
View directory record Official record
Conditions
Stage III Colorectal Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 3:09 PM EDT
Active, not recruiting Early Phase 1 Interventional

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02659241
View directory record Official record
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Carcinomatosis, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Adavosertib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Portland, Oregon • Conroe, Texas • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 6:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT02638090
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Vorinostat
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 7:50 AM EDT